Jun 10, 2015 02:50PM Roth Sees Peregrine Pharma (PPHM) Entering Key Execution Phase; Affirms at 'Buy'

Apr 20, 2015 09:59AM Roth Capital Remains Positive on Peregrine Pharma (PPHM) Following Bavituximab Presentation

Jan 16, 2015 01:55PM Peregrine Pharma (PPHM) Starts 2015 Right with Strong Bavituximab in HCC Data - Roth Capital

Dec 11, 2014 09:58AM Roth Afirms Peregrine Pharma (PPHM) at Buy Following Q2 Numbers; Looking to Data-Heavy 2015

Oct 30, 2014 02:35PM Peregrine's (PPHM) Phase Ib IST of Bavituximab Important Progress in Development as NSCLC Treatment - Roth

Jul 15, 2014 09:56AM Roth Capital Affirms Peregrine Pharma (PPHM) at 'Buy'; Remains Encouraged by Progress in FY14

Apr 23, 2014 09:56AM Roth 'Encouraged' to See Bavituximab Moving Forward; Affirms Peregrine Pharma (PPHM) at 'Buy'

Mar 14, 2014 02:14PM Roth Reaffirms Peregrine Pharma (PPHM) at Buy; Prelim. Bavituximab + Sorafenib Phase I/II is Positive

Mar 7, 2014 12:06PM Peregrine (PPHM) Risk/Reward Still Favorable; Plenty to Look Forward to in FY14 - Roth

Jan 7, 2013 08:50AM Roth Capital Upgrades Peregrine Pharmaceuticals (PPHM) to Buy

Sep 24, 2012 09:19AM Roth Capital Downgrades Peregrine Pharmaceuticals (PPHM) to Neutral

Sep 10, 2012 07:55AM Peregrine Pharmaceuticals (PPHM) Price Target Nearly Doubled

Aug 15, 2012 11:32AM Peregrine Pharmaceuticals (PPHM) Goes Red to Green

Aug 15, 2012 10:17AM Peregrine Pharmaceuticals (PPHM) Falls Despite Positive Mention

Mar 12, 2012 08:53AM Roth Capital removed Peregrine Pharmaceuticals (PPHM) from its Focus List